- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04623333
A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer
November 9, 2020 updated by: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Single-arm, Open-label, Multicenter, Phase II Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer
This is a study to evaluate the efficacy and safety of TQB2450 injection in the treatment of PD-L1 positive recurrent or metastatic cervical cancer.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
80
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Beihua Kong, Doctor
- Phone Number: 0531-82166671
- Email: kongbeihua@sdu.edu.cn
Study Locations
-
-
Shangdong
-
Jinan, Shangdong, China, 250012
- Qilu Hospital Of Shandong University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- 1. Understood and signed an informed consent form; 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; Life expectancy ≥ 3 months; 3. Diagnosed as recurrent or metastatic cervical cancer; 4. Has received ≥first-line platinum-containing chemotherapy, and disease progress or recur during or after treatment; 5. PD-L1 positive, and the combined positive score (CPS) ≥1; 6. Has at least one measurable lesion; 7. Adequate laboratory indicators; 8. Serum or urine pregnancy tests are negative within 7 days before randomization; Men and women should agree to use effective contraception during the study period and after the end of the study period within 6 months.
Exclusion Criteria:
- 1. Combined diseases and medical history: a) Has diagnosed and/or treated additional malignancy within 3 years prior to first dose;b) Diagnosed as other special pathological types, such as mucinous adenocarcinoma, clear cell adenocarcinoma, neuroendocrine tumor and so on;c) Unalleviated toxicity ≥ grade 1 due to any previous anticancer therapy;d) Has received major surgical treatment, open biopsy and so on within 28 days before the start of the study;e) Has a unhealed wound or fracture for a long time; f) Has cerebrovascular accident, deep vein thrombosis and pulmonary embolism within 6 months before the study; g) Has a history of psychotropic substance abuse and unable to quit or mental disorders; h)Has any serious and / or uncontrolled disease; 2.Tumor-related symptoms and treatment: a) Has received surgery, chemotherapy, radiotherapy or other anticancer therapy within 4 weeks before the start of the study; b) Has received proprietary Chinese medicine with anti-tumor indications in the NMPA approved drug instructions within 2 weeks before the start of the study; c) Has received immunotherapeutic drugs against PD-1, PD-L1, CTLA-4 and other related drugs; d) Has uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage; e) Has symptomatic central nervous system (CNS) disease and/or cancerous meningitis, pia mater disease; 3. Related to treatment of research: a) Has received attenuated live vaccine within 28 days before first dose or planned to received attenuated live vaccine during the study period; b) Has severe hypersensitivity reactions after using monoclonal antibodies; c) Has active autoimmune diseases requiring systemic treatment occurred within 2 years before the study; d) Has a history of active tuberculosis; 4.Has Participated in other clinical trials within 4 weeks before first dose. 5.According to the judgement of the investigators, there are other factors that may lead to the termination of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: TQB2450 injection
TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
|
TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR) evaluated by Independent Review Committee (IRC)
Time Frame: up to 12 months
|
ORR defined as percentage of participants achieving complete response (CR) and partial response (PR), recorded from the first dose until the first documented progressive disease (PD) or death from any cause, based on IRC.
|
up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR) evaluated by investigator
Time Frame: up to 12 months
|
ORR defined as percentage of participants achieving complete response (CR) and partial response (PR), recorded from the first dose until the first documented progressive disease (PD) or death from any cause, based on investigator.
|
up to 12 months
|
Duration of response (DOR)
Time Frame: up to 12 months
|
The time when the participants first achieved complete or partial remission to disease progression.
|
up to 12 months
|
Disease Control Rate (DCR)
Time Frame: up to 12 months
|
Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).
|
up to 12 months
|
Progression free survival (PFS)
Time Frame: up to 12 months
|
PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.
|
up to 12 months
|
Overall survival (OS)
Time Frame: up to 18 months
|
OS defined as the time from randomization to death from any cause.
Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.
|
up to 18 months
|
DOR rate (≥ 6 months)
Time Frame: up to 12 months
|
The percentage of participants achieved complete or partial remission ≥ 6 months.
|
up to 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
November 30, 2020
Primary Completion (ANTICIPATED)
December 31, 2022
Study Completion (ANTICIPATED)
June 30, 2023
Study Registration Dates
First Submitted
November 9, 2020
First Submitted That Met QC Criteria
November 9, 2020
First Posted (ACTUAL)
November 10, 2020
Study Record Updates
Last Update Posted (ACTUAL)
November 10, 2020
Last Update Submitted That Met QC Criteria
November 9, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TQB2450-II-09
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent or Metastatic Cervical Cancer
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingRecurrent or Metastatic Cervical CancerChina
-
Guangzhou Gloria Biosciences Co., Ltd.Not yet recruitingPersistent, Recurrent, or Metastatic Cervical CancerChina
-
Shanghai OriginCell Therapeutics Co., Ltd.Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineRecruitingTILs, Metastatic or Recurrent Cervical CancerChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingRecurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
-
University of South AlabamaExelixisTerminatedCervical Cancer | Metastatic Cervical Cancer | Recurrent Cervical Cancer | Persistent Cervical CancerUnited States
-
Dana-Farber Cancer InstituteAstraZenecaTerminatedRecurrent Ovarian Carcinoma | Recurrent Cervical Carcinoma | Recurrent Endometrial Cancer | Metastatic Endometrial Cancer | Metastatic Cervical Cancer | Recurrent Vaginal Cancer | Recurrent Vulvar Cancer | Metastatic Ovarian Cancer | Recurrent Gynecological Cancer | Metastatic Vaginal Cancer | Metastatic...United States
-
AkesoAkesobio Australia Pty LtdCompletedMetastatic Cervical Cancer | Recurrent Cervical CancerUnited States, Australia, New Zealand
-
BiocadUnknownCervical Cancer | Cervical Cancer Recurrent | Cervical Cancer MetastaticRussian Federation
-
Sun Yat-sen UniversityCompletedRecurrent Cervical Carcinoma | Metastatic Cervical CancerChina
-
Gang Chen (101199)Not yet recruitingRecurrent or Metastatic Cervical Cancer
Clinical Trials on TQB2450
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingAdvanced Oligometastatic Non-small Cell Lung CancerChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Unknown
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Unknown
-
Jiangxi Provincial Cancer HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingDigestive System Diseases | Gastrointestinal Diseases | Neoplasms by Histologic Type | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Carcinoma, Squamous Cell | Esophageal Neoplasms | Esophageal Diseases | Neoplasms, Squamous Cell | Esophageal Squamous Cell CarcinomaChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownAdvanced Solid TumorsChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingStage III Non-small-cell Lung CancerChina
-
Fudan UniversityRecruiting
-
Tianjin Medical University Cancer Institute and...Recruiting
-
Chinese PLA General HospitalNot yet recruitingHepatocellular Carcinoma | Anlotinib | Thermal Ablation | PDL-1China